Cargando…

Preliminary Report on HIV-1 Vaccine Preparedness in Nigeria: Advantages of Recruiting University Students

The national HIV seroprevalence in Nigeria has risen steeply from about 3% in 1993 to 5–8% in 2001 and now stands at 4.4%. HIV epidemic continues to be a serious threat to the most populous country in Africa with a population of 140 million, with limited use of antiviral drugs that is taken for life...

Descripción completa

Detalles Bibliográficos
Autores principales:	Edubio, Abigail, Agwale, Simon, Bulterys, Marc, Jelpe, Dadik, Idoko, John, Isichei, Chris, Guyit, Ruth, Abimiku, Alash’le
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Molecular Diversity Preservation International (MDPI) 2010
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185563/ https://www.ncbi.nlm.nih.gov/pubmed/21994601 http://dx.doi.org/10.3390/v2010073

Ejemplares similares

Diagnostic system strengthening for drug resistant tuberculosis in Nigeria: impact and challenges
por: Aliyu, Gambo, et al.
Publicado: (2017)

Development of a prospective cohort of HIV Exposed Sero-Negative (HESN) individuals in Jos Nigeria
por: Osawe, Sophia, et al.
Publicado: (2016)

Cost-effectiveness of point-of-care digital chest-x-ray in HIV patients with pulmonary mycobacterial infections in Nigeria
por: Aliyu, Gambo, et al.
Publicado: (2014)

Prevalence of Non-Tuberculous Mycobacterial Infections among Tuberculosis Suspects in Nigeria
por: Aliyu, Gambo, et al.
Publicado: (2013)

Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria
por: Bada, Florence O., et al.
Publicado: (2020)

Correction: Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria
por: Bada, Florence O., et al.
Publicado: (2021)

Cost of three models of care for drug-resistant tuberculosis patients in Nigeria
por: Bada, Florence O., et al.
Publicado: (2019)

Characterisation of HIV-1 Molecular Epidemiology in Nigeria: Origin, Diversity, Demography and Geographic Spread
por: Nazziwa, Jamirah, et al.
Publicado: (2020)

Assuring the quality of diagnostic testing: The future is now
por: Nkengsong, John, et al.
Publicado: (2016)

Community stakeholder engagement during a vaccine demonstration project in Nigeria: lessons on implementation of the good participatory practice guidelines
por: Folayan, Morenike Oluwatoyin, et al.
Publicado: (2019)

Mycobacterial Etiology of Pulmonary Tuberculosis and Association with HIV Infection and Multidrug Resistance in Northern Nigeria
por: Aliyu, Gambo, et al.
Publicado: (2013)

Demography and the dual epidemics of tuberculosis and HIV: Analysis of cross-sectional data from Sub-Saharan Africa
por: Aliyu, Gambo, et al.
Publicado: (2018)

Performance and trend for quality of service in a large HIV/AIDS treatment program in Nigeria
por: Aliyu, Ahmad, et al.
Publicado: (2019)

Implementing quality assurance for laboratory-based and point-of-care HIV testing in Nigeria
por: Abubakar, Ado, et al.
Publicado: (2016)

Factors associated with receipt of a timely infant birth dose of hepatitis B vaccine at a tertiary hospital in North-Central Nigeria
por: Bada, Florence O., et al.
Publicado: (2022)

Missed opportunities for early infant diagnosis of HIV in rural North-Central Nigeria: A cascade analysis from the INSPIRE MoMent study
por: Anaba, Udochisom C., et al.
Publicado: (2019)

The role of connected diagnostics in strengthening regional, national and continental African disease surveillance
por: Gous, Natasha M., et al.
Publicado: (2018)

Evaluation of accuracy and performance of self-reported HIV and antiretroviral therapy status in the Nigeria AIDS Indicator and Impact Survey (2018)
por: Jahun, Ibrahim, et al.
Publicado: (2022)

A23 Identification of HIV drug resistance mutation patterns using illumina MiSeq next generation sequencing in patients failing second-line boosted protease inhibitor therapy in Nigeria
por: James, Onyemata E., et al.
Publicado: (2017)

Immuno-virologic outcomes and immuno-virologic discordance among adults alive and on anti-retroviral therapy at 12 months in Nigeria
por: Anude, Chuka J, et al.
Publicado: (2013)

Performance of HIV rapid testing algorithm in Nigeria: Findings from a household-based Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS)
por: Patel, Hetal K., et al.
Publicado: (2022)

Immunity in Nigerian women and the effects of pregnancy and infectious disease exposure on fetal immunity
por: Cairo, Cristiana, et al.
Publicado: (2006)

Effect of community antiretroviral therapy on treatment outcomes among stable antiretroviral therapy patients in Nigeria: A quasi experimental study
por: Dakum, Patrick, et al.
Publicado: (2021)

TLR10 Senses HIV-1 Proteins and Significantly Enhances HIV-1 Infection
por: Henrick, Bethany M., et al.
Publicado: (2019)

Prevalence and characteristics of metabolic syndrome and its components among adults living with and without HIV in Nigeria: a single-center study
por: Jumare, Jibreel, et al.
Publicado: (2023)

Implementing an intensified mentorship approach towards accelerated medical laboratory accreditation in 10 counties in Kenya
por: Musau, Susan K., et al.
Publicado: (2022)

Evaluation of the Nigeria national HIV rapid testing algorithm
por: Iriemenam, Nnaemeka C., et al.
Publicado: (2022)

HIV Viral Dynamics of Lopinavir/Ritonavir Monotherapy as Second-Line Treatment: A Prospective, Single-Arm Trial
por: Claassen, Cassidy W., et al.
Publicado: (2019)

Associations between Cognition, Gender and Monocyte Activation among HIV Infected Individuals in Nigeria
por: Royal, Walter, et al.
Publicado: (2016)

Expression profiling of human milk derived exosomal microRNAs and their targets in HIV-1 infected mothers
por: Zahoor, Muhammad Atif, et al.
Publicado: (2020)

Patient Retention and Adherence to Antiretrovirals in a Large Antiretroviral Therapy Program in Nigeria: A Longitudinal Analysis for Risk Factors
por: Charurat, Man, et al.
Publicado: (2010)

Implementation of data triangulation and dashboard development for COVID-19 vaccine adverse event following immunisation (AEFI) data in Nigeria
por: Shragai, Talya, et al.
Publicado: (2023)

Comprehensive Reference Ranges for Hematology and Clinical Chemistry Laboratory Parameters Derived from Normal Nigerian Adults
por: Miri-Dashe, Timzing, et al.
Publicado: (2014)

Prevalence of hypertension among patients aged 50 and older living with human immunodeficiency virus
por: Dakum, Patrick, et al.
Publicado: (2019)

H3Africa: current perspectives
por: Mulder, Nicola, et al.
Publicado: (2018)

Optimising Mycobacterium tuberculosis detection in resource limited settings
por: Alfred, Nwofor, et al.
Publicado: (2014)

Genes for Life: Biobanking for Genetic Research in Africa
por: Mayne, Elizabeth Sarah, et al.
Publicado: (2017)

Performance of SARS COV-2 IgG Anti-N as an Independent Marker of Exposure to SARS COV-2 in an Unvaccinated West African Population
por: Abdullahi, Adam, et al.
Publicado: (2023)

Longitudinal gut microbiota composition of South African and Nigerian infants in relation to tetanus vaccine responses
por: Iwase, Saori C., et al.
Publicado: (2023)

Predictors of first-line antiretroviral therapy failure among adults and adolescents living with HIV/AIDS in a large prevention and treatment program in Nigeria
por: Ndembi, Nicaise, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5lbem084khigu3muqjrm8cf2r2